F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, vol.68, issue.6, pp.394-424, 2018.

, , vol.374, pp.61338-61344

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer Statistics, CA Cancer J Clin, vol.67, issue.1, pp.7-30, 2017.

C. R. Bankhead, S. T. Kehoe, and J. Austoker, Symptoms associated with diagnosis of ovarian cancer: a systematic review, BJOG, vol.112, issue.7, pp.857-865, 2005.

J. S. Berek, S. T. Kehoe, L. Kumar, and M. Friedlander, Cancer of the ovary, fallopian tube, and peritoneum, Int J Gynaecol Obstet, vol.143, issue.2, pp.59-78, 2018.

I. Lataifeh, D. E. Marsden, G. Robertson, V. Gebski, and N. F. Hacker, Presenting symptoms of epithelial ovarian cancer, Aust N Z J Obstet Gynaecol, vol.45, issue.3, pp.211-214, 2005.

S. J. Kim, B. Rosen, and I. Fan, Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer, Br J Cancer, vol.116, issue.7, pp.964-971, 2017.

A. Elattar, A. Bryant, B. A. Winter-roach, M. Hatem, and R. Naik, Optimal primary surgical treatment for advanced epithelial ovarian cancer, Cochrane Database Syst Rev, issue.8, p.7565, 2011.

C. Ang, K. Chan, A. Bryant, R. Naik, and H. O. Dickinson, Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer, Cochrane Database Syst Rev, issue.4, p.7697, 2011.

M. Luyckx, E. Leblanc, and T. Filleron, Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study, Int J Gynecol Cancer, vol.22, issue.8, pp.1337-1343, 2012.

V. Sopik, J. Iqbal, B. Rosen, and S. A. Narod, Why have ovarian cancer mortality rates declined? Part II. Case-fatality, Gynecol Oncol, vol.138, issue.3, pp.750-756, 2015.

W. R. Robinson, J. Beyer, S. Griffin, and P. Kanjanavaikoon, Extraperitoneal metastases from recurrent ovarian cancer, Int J Gynecol Cancer, vol.22, issue.1, pp.43-46, 2012.

A. Gadducci, S. Cosio, and P. Zola, The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study, Gynecol Oncol, vol.116, issue.3, pp.358-363, 2010.

A. Ferrero, A. Ditto, and G. Giorda, Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study, Eur J Surg Oncol, vol.40, issue.7, pp.891-898, 2014.

A. Santillan, A. K. Karam, and A. J. Li, Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer, Gynecol Oncol, vol.104, issue.3, pp.686-690, 2007.

C. Uzan, P. Morice, and A. Rey, Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes

, Ann Surg Oncol, vol.11, issue.7, pp.658-664, 2004.

P. Blanchard, A. Plantade, and C. Pagès, Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors, Gynecol Oncol, vol.104, issue.1, pp.41-45, 2007.

F. Legge, M. Petrillo, V. Adamo, S. Pisconti, G. Scambia et al., Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome, BMC Cancer, vol.8, p.367, 2008.

P. Benedetti-panici, G. Perniola, and R. Angioli, Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer, Int J Gynecol Cancer, vol.17, issue.6, pp.178-182, 2007.

G. Rustin, I. Vergote, and E. Eisenhauer, Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), Int J Gynecol Cancer, vol.21, issue.2, pp.419-423, 2011.

E. A. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, issue.2, pp.228-247, 2009.

K. Gasimli, E. I. Braicu, and M. Nassir, Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network, Ann Surg Oncol, vol.23, issue.4, pp.294-300, 2005.

D. S. Chi, J. N. Barlin, and P. T. Ramirez, Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller, Int J Gynecol Cancer, vol.20, issue.3, pp.353-357, 2010.

E. Sala, L. Mannelli, and K. Yamamoto, The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer, Int J Gynecol Cancer, vol.21, issue.2, pp.296-301, 2011.

Y. Chen, T. Chen, C. Zee, Y. Shi, L. Wan et al.,

, PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center, Nucl Med Commun, vol.35, issue.4, pp.347-352, 2014.

H. Tu, H. Huang, Q. Huang, Z. Li, Y. Feng et al.,

, Zhonghua Fu Chan Ke Za Zhi, vol.47, issue.12, pp.928-933, 2012.

S. Chang, R. E. Bristow, and H. Ryu, Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer, Ann Surg Oncol, vol.19, issue.13, pp.4059-4067, 2012.

M. Peiretti, V. Zanagnolo, and G. D. Aletti, Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes, Gynecol Oncol, vol.119, issue.2, pp.259-264, 2010.

F. Joulie, P. Morice, and A. Rey, Are nodal metastases in ovarian cancer chemoresistant lesions? Comparative study of initial lymphadenectomy or after chemotherapy

, Gynecol Obstet Fertil, vol.32, issue.6, pp.502-507, 2004.

M. Lee, S. W. Kim, and S. H. Lee, Comparison of the efficacy and toxicity between radiotherapy and chemotherapy in nodal and isolated nonnodal recurrence of ovarian cancer

, Int J Gynecol Cancer, vol.21, issue.6, pp.1032-1039, 2011.

M. Bommert, P. Harter, F. Heitz, D. Bois, and A. , When should Surgery be used for Recurrent Ovarian Carcinoma?, Clin Oncol (R Coll Radiol), vol.30, issue.8, pp.493-497, 2018.

W. Szczesny, H. Langseth, T. Å. Myklebust, J. Kaern, C. Tropé et al., Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study, Acta Obstet Gynecol Scand, 2018.

P. G. Rose, S. Nerenstone, M. F. Brady, D. Clarke-pearson, G. Olt et al., Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma, N Engl J Med, vol.351, issue.24, pp.2489-97, 2004.

J. Zhou, J. Sun, and S. Wu, Risk factors for lymph node metastasis in ovarian cancer: Implications for systematic lymphadenectomy, Int J Surg, vol.29, pp.123-127, 2016.

P. Morice, F. Joulie, and S. Camatte, Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications, J Am Coll Surg, vol.197, issue.2, pp.3849-3855, 2003.

R. Rouzier, C. Bergzoll, and J. Brun, The role of lymph node resection in ovarian cancer: analysis of the Surveillance, Epidemiology, and End Results (SEER) database, BJOG, vol.117, issue.12, pp.1451-1458, 2010.

R. L. Hollis, J. Carmichael, A. M. Meynert, M. Churchman, T. Hallas-potts-a-2-,-rye et al., Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse

, Am J Obstet Gynecol, vol.221, issue.3, p.245, 2019.